AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
BIOWA LICENSES ANTI IL-5 RECEPTOR ANTIBODY FROM KYOWA HAKKO KOGYO.
(From Asia Pulse)
(Full text of statement. Contact details below.)
PRINCETON, N.J., March 23 /PRNewswire-AsiaNet/ --
BioWa announced today that it has successfully licensed from Kyowa Hakko Kogyo Co., Ltd. (Tokyo, Osaka, Nagoya, Fukuoka, Sapporo: 4151), its parent company, the exclusive worldwide rights, except Asia, to develop and commercialize anti IL-5 receptor antibody, a potential new asthma treatment.
Under the terms of the agreement, BioWa expects to develop and commercialize anti IL-5 receptor antibody, which is currently in late pre- clinical development, in the US and Europe. In return, Kyowa Hakko Kogyo Co. has an option to develop and commercialize the product in Asia and will be responsible for all development activities and costs. Under the terms of the agreement, BioWa retains all rights to anti IL-5 receptor antibody in non-Asia countries. Each …
-
- BioWa Inc licenses anti IL-5 receptor antibody from Kyowa Hakko Kogyo Co Ltd.
-
News wire article from: Asia Africa Intelligence Wire
March 22, 2005
700+ words
-
- APPTEC AND BIOWA ENTER INTO AGREEMENT FOR SERVICES.
-
News wire article from: Asia Africa Intelligence Wire
July 13, 2005
700+ words
-
- Media Release: BioWa, Inc.; AppTec Laboratory Services, IncAAP MEDIANET...
-
News wire article from: Asia Africa Intelligence Wire
July 13, 2005
700+ words
-
- AppTec and BioWa enter into agreement for services.
-
News wire article from: Asia Africa Intelligence Wire
July 13, 2005
700+ words
-
- Event Brief of Roche's Analyst Briefing on data presented at EULAR -...
-
News wire article from: Fair Disclosure Wire
June 15, 2007
700+ words
